Main Text
(Molecular Therapy: Methods & Clinical Development 24, 127–141; March 2022)
After additional analyses of integration sites, we found that the following sentence in the originally published version of this article is inaccurate: “No integration within or near any proto-oncogene was found.”
The corrected acknowledgement now appears below:
“The integration pattern is in conjunction with a previously determined pattern1. Notably, the current method of integration site analysis does not allow for measuring the frequency of individual integration sites and potential clonal expansion. Additional studies are required to assess cancer-related genotoxicity of the HDAd-SB100x transposase system after in vivo HSC transduction in NHPs.”
The authors regret this error.
References
- 1.Rotiroti M.C., Buracchi C., Arcangeli S., Galimberti S., Valsecchi M.G., Perriello V.M., Rasko T., Alberti G., Magnani C.F., Cappuzzello C., Lundberg F., et al. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System. Mol. Ther. 2020;28:1974–1986. doi: 10.1016/j.ymthe.2020.05.021. [DOI] [PMC free article] [PubMed] [Google Scholar]